IWWM-12 Poster A01 - A35 Abstracts

The following abstracts represent the poster presentations (A01-A35) given at IWWM-12 (Prague-2024)

Session Chairs: Andrew Branagan and Josephine Vos

A01: Long term follow-up of rituximab for anti-myelin-associated glycoprotein demyelinating polyneuropathy in lgM gammopathies: clinical, hematological and neurophysiological correlations Enrico Amaducci

A02: lbrutinib or chemo-immunotherapy as second line treatment in Waldenstrom Macroglobulinaemia? A real-life multicentre study Francesco Autore

A03: Single-Center Experience, Clinical Spectrum, and Prognosis of Patients with lgM AL Amyloidosis Emilia-Larisa Zidaru

A04: Clinical Diversity and Treatment Outcomes in lgM MGUS/Waldenstrom disease Associated with Cold Agglutinin Disease and Cryoglobulinemia: A Single-Center Study Emilia-Larisa Zidaru

A05: Zanubrutinib is effective in the treatment of patients with Waldenstrom's macroglobulinemia and Bing-Neel syndrome: a retrospective multicenter study Julia Bannatyne Undabeitia

A06: Bone marrow pathology in cold agglutinin disease and distinction from other B-cell disorders: Preliminary results of the Re-CAD study Anne-Marie Becking

A07: Comorbidity, age and sex in relation to survival among 2264 patients with Waldenstrom's macroglobulinemia - a Swedish Lymphoma Registry Study Lena Brandefors

A08: immunogenetic landscape of Waldenstrom Macroglobulinemia: correlation with clinicobiological features, prognosis and comparison with physiological memory-B cells and plasma cells Clotilde Bravetti

A09: The presence of >=10% bone marrow plasma cells at diagnosis is associated with shorter time to first treatment in patients with Waldenstrom's Macroglobulinemia: results from from the observational prospective and retrospective BIO-WM study of Fondazione ltaliana Linfomi Emilia Cappello

A10: Treatment With lopofosine I 131 in a Patient With Bing-Neel Syndrome, A Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report Jorge Castillo

A11: Detection of Recurrent Mutations, lmmunoglobulin Rearrangements and Copy Number Changes in cell-free DNA and Bone Marrow on Patients with Waldenstrom's Macroglobulinemia over a Course of Treatment Signy Chow

A12: Data Analytics of Treatment effects on Immune Response Pathways within the Tumour Microenvironment of Waldenstrom Macroglobulinaemia Amy Christian

A13: Real-Life Multicenter Study On Behalf Of The Fondazione Italiana Linfomi Investigating Renal Dysfunction In Waldenstrom Macroglobulinemia: Clinical Outcomes And Management Strategy Nicolo Danesin

A14: Bendamustine-rituximab for anti-myelin-associated-glycoprotein neuropathy: a retrospective study of 33 patients Annabel de Nettancourt

A15: Baseline laboratory characteristics of the UK RAINBOW trial cohort: phenotypic and genomic features Ruth de Tute

A16: Role of Inflammation in Waldenstrom Macroglobulinemia: Insights from a Multicenter Study Pierre-edouard Debureaux

A17: Exploring the cell-free transcriptome as biomarker source in lgM gammopathies: new insights from the Fl L "BIO-WM" trial Phillipe Decruyenaere

A18: Determining outcome in lgM gammopathies: integration of molecular, flow cytometry and clinical factors in an international, multicenter series (the SAL-TO study) Irene Dogliotti

A19: Non-invasive MYD88L256P detection and MRD analysis by ddPCR in cfDNA in the ECWM2 international, multicentric phase II trial Daniela Drandi

A20: A novel dual HDAC6 and proteasome inhibitor elicits outstanding cytotoxicity against multiple myeloma Teng Fang

A21: TRIM28 functions as a key protein homeostasis regulator and mediates Pl resistance in Multiple myeloma Teng Fang

A22: Free Light Chain (FLC) Ratio is an Independent Risk Factor for Progression to Symptomatic Waldenstrom's Macroglobulinemia in Patients with lgM Monoclonal Gammopathy of Undetermined Significance, lgM-related disorders or Aymptomatic Waldenstrom's Macroglobulinemia Gianmarco Favrin

A23: Epigenetic liquid biopsy for diagnosis and surveillance of Waldenstrom macroglobulinemia Ilana Fox-Fisher

A24: Salvage treatment after BTKi failure: an unmet need in clinical practice in Waldenstrom macroglobulinemia Anna-Maria Frustaci

A25: Dissecting The Oncogenic Functions of MYD88 Mutations and Chromosome 6q Deletion in Waldenstrom's Macroglobulinemia Filip Garbicz

A26: A challenging case of Bing Neel Syndrome (BNS) treated with zanubrutinib, followed by BCNU-Thiotepa conditioned autologous stem cell transplant (ASCT) Medha Ratnayake

A27: Changes in the Overall Survival of Patients with Waldenstrom's Macroglobulinemia After the Introduction of Modern Targeted Therapies Maria Gavriatopoulou

A28: Tumor Associated Macrophages' cytokines; CD163, CCL4, CCL2 and IL-10 as possible new biomarkers in Waldenstrom's Macroglobulinemia with emphasis on AWM Alexandros Gkiokas

A29: Peripheral Neuropathy in Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenstrom Macroglobulinemia Benjamin Heyman

A30: Use of Intravenous lmmunoglobulin for Secondary Hypogammaglobulinemia Following Treatment in Waldenstrom's Macroglobulinaemia Nicole Japzon

A31: Incidence, Risk Factors and Outcomes of Second Primary Malignancies in Waldenstrom's Macroglobulinaemia Nicole Japzon

A32: Multicenter prospective phase II study of rituximab combined, bortezomib, lenalidomide, dexamethasone followed by lenalidomide maintenance (R-VRD) in patients with Waldenstrom's macroglobulinemia (KMM 1803) Sung-Hoon Jung

A33: Treatment and Survival Outcomes of Symptomatic Waldenstrom's Macroglobulinemia in the Czech Republic Over the Last 10 Years: A Retrospective Analysis from the Registry of Monoclonal Gammopathies Michal Kascak

A34: Social deprivation affects survival in Waldenstrom Macroglobulinaemia: experience in the UK Jahanzaib Khwaja

A35: Prognostication in lgM and LPL associated systemic AL amyloidosis Jahanzaib Khwaja